Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SciBase Holding ABOSTO:SCIB +3.63%56 Cash Ratio is 2.99 as of Mar. 2026, which is 7% below its 10-year median of 3.22. GuruFocus rates OSTO:SCIB with a GF Score™ of 56/100 and a GF Value™ of kr21.72 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 841 Medical Devices & Instruments companies, SciBase Holding AB ranks better than 76.81% on this metric.
SciBase Holding AB has a Cash Ratio of 2.99. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for SciBase Holding AB's Cash Ratio or its related term are showing as below:
OSTO:SCIB'
s Cash Ratio Range Over the Past 10 Years
Min: 0.48 Med: 3.22 Max: 11.52
Current: 2.99
During the past 13 years, SciBase Holding AB's highest Cash Ratio was 11.52. The lowest was 0.48. And the median was 3.22.
OSTO:SCIB's Cash Ratio is ranked better than 76.81% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 0.97
vs OSTO:SCIB: 2.99
SciBase Holding AB (OSTO:SCIB) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
SciBase Holding AB Cash Ratio Related Terms
SciBase Holding AB Cash Ratio Historical Data
* Premium members only.
The historical data trend for SciBase Holding AB's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, SciBase Holding AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SciBase Holding AB Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SciBase Holding AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where SciBase Holding AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SciBase Holding AB (OSTO:SCIB) has a Cash Ratio of 2.99 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on SciBase Holding AB and its competitors. This is near median its historical median of 3.22. Over the past decade, SciBase Holding AB's Cash Ratio has ranged from 0.48 to 11.52. According to the industry distribution chart, SciBase Holding AB ranks #195 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 23.2%.
Is SciBase Holding AB's Cash Ratio too high?
SciBase Holding AB's current Cash Ratio of 2.99 is near median its 10-year median of 3.22. Over the past 10 years, this metric has ranged from a low of 0.48 to a high of 11.52. The Medical Devices & Instruments industry median Cash Ratio is 0.97. SciBase Holding AB's value of 2.99 is 208.2% above this industry median. Based on the distribution chart, SciBase Holding AB ranks #195 out of 841 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, SciBase Holding AB has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SciBase Holding AB's Cash Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, SciBase Holding AB ranks #195 out of 841 companies for Cash Ratio. This places SciBase Holding AB in the top 23% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.97. SciBase Holding AB's value of 2.99 is 208.2% above this benchmark. Historically, SciBase Holding AB's own Cash Ratio has ranged from 0.48 to 11.52 over the past decade. While the company's 10-year median is 3.22 vs. the industry median of 0.97, SciBase Holding AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.97, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SciBase Holding AB's current Cash Ratio of 2.99 is 208.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on SciBase Holding AB and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SciBase Holding AB's current Cash Ratio is 2.99, which is near median its own 10-year median of 3.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SciBase Holding AB stock overvalued right now?
Based on GuruFocus' analysis, SciBase Holding AB (OSTO:SCIB) is currently considered Significantly Overvalued. The stock's GF Value™ is kr21.72, compared to a current price of kr34.30 — trading 57.9% above its estimated fair value. The current Cash Ratio is 2.99, which is near median its 10-year median of 3.22 and 208.2% above the Medical Devices & Instruments industry median of 0.97. SciBase Holding AB's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For SciBase Holding AB (OSTO:SCIB), the current Cash Ratio is 2.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SciBase Holding AB (OSTO:SCIB) Overvalued in 2026?
Based on GuruFocus' analysis, SciBase Holding AB stock appears to be overvalued.
The current stock price of kr34.30 is trading 57.9% above its estimated GF Value™ of kr21.72.
GuruFocus considers SciBase Holding AB to be Significantly Overvalued.
Key valuation signals for OSTO:SCIB:
Cash Ratio: 2.99 (near median its 10-year median of 3.22)
GF Value™: kr21.72 vs. price of kr34.30 (57.9% above fair value)
Industry Position: 208.2% above the Medical Devices & Instruments median (#195 of 841)
No single metric tells the full story. See the OSTO:SCIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SciBase Holding AB is a medical technology company specializing in early detection of skin cancer and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a point-of-care technology platform that combines AI (artificial intelligence) and EIS technology to elevate diagnostic accuracy and support the prevention of skin diseases. The company's product portfolio consists of the Nevisense platform technology for multiple clinical applications and proprietary Nevisense electrodes. The products are based on measurements using electrical impedance spectroscopy (EIS), analysed using custom artificial intelligence (AI)-based algorithms. The company operates in two segments, which include skin cancer and skin barrier assessment.
56GF Score
Get the complete analysis for OSTO:SCIB
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SCIB has been successfully added to your 
